Profile data is unavailable for this security.
About the company
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
- Revenue in CAD (TTM)0.00
- Net income in CAD-4.59m
- Incorporated2011
- Employees3.00
- LocationXORTX Therapeutics Inc3710 - 33rd Street NWCALGARY T2L 2M1CanadaCAN
- Phone+1 (403) 455-7727
- Fax+1 (403) 607-2621
- Websitehttps://www.xortx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rakovina Therapeutics Inc | 0.00 | -2.72m | 7.71m | -- | -- | 2.62 | -- | -- | -0.039 | -0.039 | 0.00 | 0.042 | 0.00 | -- | -- | -- | -53.46 | -- | -56.12 | -- | -- | -- | -- | -- | -- | -16.52 | 0.3151 | -- | -- | -- | 6.39 | -- | -- | -- |
| XORTX Therapeutics Inc | 0.00 | -4.59m | 7.84m | 3.00 | -- | 2.29 | -- | -- | -1.93 | -1.93 | 0.00 | 1.18 | 0.00 | -- | -- | -- | -42.59 | -35.42 | -45.30 | -40.37 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 72.04 | -- | 7.91 | -- |
| Therma Bright Inc | 25.80k | -2.88m | 7.90m | -- | -- | 4.31 | -- | 306.12 | -0.0115 | -0.0115 | 0.0001 | 0.0058 | 0.0076 | 0.0023 | 0.115 | -- | -84.40 | -220.66 | -165.23 | -444.57 | 98.45 | -- | -11,152.48 | -10,853.16 | 0.0447 | -184.52 | 0.0411 | -- | -82.86 | 11.13 | 35.93 | -- | 40.15 | -- |
| Crescita Therapeutics Inc | 17.92m | -2.34m | 8.38m | 78.00 | -- | 0.4631 | -- | 0.4676 | -0.1162 | -0.1162 | 0.8927 | 0.9285 | 0.6903 | 1.50 | 4.62 | -- | -9.01 | -0.2457 | -11.40 | -0.3059 | 56.03 | 63.41 | -13.06 | -0.3518 | 2.60 | -- | 0.0594 | -- | -25.52 | 1.05 | -330.39 | -- | -1.58 | -- |
| Khiron Life Sciences Corp | 16.14m | -30.66m | 9.30m | 310.00 | -- | -- | -- | 0.5761 | -0.1674 | -0.1674 | 0.085 | 0.1248 | 0.3078 | 1.33 | 3.90 | 52,055.68 | -58.47 | -- | -69.10 | -- | 19.51 | -- | -190.00 | -- | 0.9133 | -- | 0.0864 | -- | 59.60 | -- | -37.81 | -- | -- | -- |
